Such molecular signatures composed of multiple pathways established the foundation for further global identification of biomarkers and therapeutic targets in HNSCC and other cancers with phenotypic and genetic heterogeneity related to p53 status or other abnormalities. This evidence concerns the gene TP53 and cancer.